Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atrish Bagchi

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cell Reports|December 3, 2014
Complex relationship between ligand binding and dimerization in the epidermal growth factor receptorNicholas J Bessman, Atrish Bagchi, Kathryn M Ferguson, et al.
Biochemical and Biophysical Research Communications|September 17, 2023
F77 antigen is a promising target for adoptive T cell therapy of prostate cancerPayal Grover, Selene Nunez-Cruz, John Leferovich, et al.
Structure (London, England : 1993)|June 25, 2013
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domainsKarl R Schmitz, Atrish Bagchi, Rob C Roovers, et al.
Molecular Genetics & Genomic Medicine|October 6, 2015
EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid featuresRebecca Ganetzky, Erin Finn, Atrish Bagchi, et al.
Molecular Cancer Therapeutics|November 22, 2017
Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab ResistanceAtrish Bagchi, Jaafar N Haidar, Scott W Eastman, et al.
Structure (London, England : 1993)|June 22, 2024
Structural insights into the role and targeting of EGFRvIIIAtrish Bagchi, Steven E Stayrook, Katerina T Xenaki, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cell Reports|December 3, 2014
Complex relationship between ligand binding and dimerization in the epidermal growth factor receptorNicholas J Bessman, Atrish Bagchi, Kathryn M Ferguson, et al.
Biochemical and Biophysical Research Communications|September 17, 2023
F77 antigen is a promising target for adoptive T cell therapy of prostate cancerPayal Grover, Selene Nunez-Cruz, John Leferovich, et al.
Structure (London, England : 1993)|June 25, 2013
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domainsKarl R Schmitz, Atrish Bagchi, Rob C Roovers, et al.
Molecular Genetics & Genomic Medicine|October 6, 2015
EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid featuresRebecca Ganetzky, Erin Finn, Atrish Bagchi, et al.
Molecular Cancer Therapeutics|November 22, 2017
Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab ResistanceAtrish Bagchi, Jaafar N Haidar, Scott W Eastman, et al.
Structure (London, England : 1993)|June 22, 2024
Structural insights into the role and targeting of EGFRvIIIAtrish Bagchi, Steven E Stayrook, Katerina T Xenaki, et al.
Pageof 1